Experiments in a pharmacological model of schizophrenia-like cognitive deficits induced by repeated ketamine administration showed the effect of cannabidiol (CBD) on the Cx3cr1 transcript level [191]. The gene discussed is CX3CR1; the disease is schizophrenia.